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Human immunodeficiency virus (HIV), which progresses into the disease commonly 
referred to as Acquired Immunodeficiency syndrome (AIDS), has become one of the world’s 
most destructive epidemics since its discovery in the early 80’s.  To date, the virus has killed 
more than 25 million people, with an average of 5 million newly infected cases last year alone.  
The HIV-1 genome is comprised of structural and enzymatic polyproteins as well as 
regulatory/accessory, which are essential for viral replication.  Viral protein R (Vpr), which is 
identified as one of the regulatory/accessory genes, is responsible for carrying out several of the 
virus’ life functions, including virus replication, cell cycle regulation, apoptosis, and immune 
dysregulation.  Through research of the virus, the disease has been divided into two very 
distinctive categories: Rapid Progressors (RPs) and Long Term Non-Progressors (LTNPs).  The 
differences between these categories are due to the varying quasispecies, which infect the 
population, and ultimately disease progression.  Several well-known mutations that occur within 
vpr have been associated with disease progression, linking them to one of the category types.  
Using a population from the Multicenter AIDS Cohort Study (MACS), patient vpr genotypes 
were analyzed and compared with current findings in research.  Several of the patients’ deduced 
amino acid sequences revealed different gene variants, truncations, as well as a number of point 
mutations.  Functional analysis revealed a decrease in cell apoptosis, which could have been 
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caused by the observed point mutations.  Further analysis is needed in order to determine if any 
other functions of the virus are disrupted due to the observed mutations.  Because the virus has 
the ability to make changes within, as of right now the only hope in counteracting the effects of 
HIV is through the use of antiviral medication, such as HAART.  But studies have shown that 
not everyone has the same positive effect when these drugs are administered.  By understanding 
the virus and its pathogenesis, researchers will be able to develop new targets for therapeutic 
interventions. The public health significance of this project is to provide the valuable research 
that will lead towards such viable HIV-1 therapeutic interventions. 
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1.0  HIV-1/AIDS 
Human Immunodeficiency virus type 1 (HIV-1) is the etiologic agent of Acquired 
Immunodeficiency syndrome (AIDS).  As of Dec. 2005, the total number of people living with 
the human immunodeficiency virus (HIV) reached its highest level: an estimated 45 million 
[36.7–45.3 million] people are now living with HIV. AIDS has killed more than 25 million 
people since it was first recognized in 1981, making it one of the most destructive epidemics in 
recorded history. Despite the recent introduction of highly active antiretroviral treatment 
(HAART), the AIDS epidemic claimed 3.1 million [2.8–3.6 million] lives in 2005; more than 
half a million (570 000) were children (1). 
HIV belongs to the Retroviridae family under the genus classification of lentivirus (2).  
Lentiviruses are known for causing immune deficiencies as well as disorders of the 
hematopoietic and central nervous systems, arthritis, and, autoimmunity (2).  To better help with 
the classification of cases, HIV-1 has been divided into three groups based on geographical 
location.  The first group identified was group M, which stands for main.  As its name implies, 
this group encompasses the majority of the world’s HIV/AIDS pandemic (3).  It is estimated that 
that around 42 million people are infected by group M virus (3).  The next is group O, which 
stands for outliers, and can mainly be found in Cameroon.  Only tens of thousands of people are 
estimated to have been infected by this particular virus (3).  Lastly is group N, the newest group 
to be identified.  Group N has been identified as a mixture of either M and N, or O and N, but is 
not comprised of an entirely unique genome.  Research has shown HIV is most probably of a 
zoonotic origin, while the emergence of this virus is suggested to have resulted from three 
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independent cross-species transmission events, which gave rise to the aforementioned three 
groups (3).  Research has suggested that the source of HIV-1 is the central African chimpanzee.  
This is supported by the fact that the groups are more closely related to SIVcpz strains that 
infected central African chimpanzees, Pan troglodytes troglodytes (SIVcpzPTT) than the Pan 
troglodytes schweinfurthii strain which infects the east African chimpanzees (3). 
Since HIV-1 is a viral agent, it must find a host with the proper mechanics in which to 
live and reproduce. Viral transmission from one host to another can occur in one of three ways: 
1) contact with blood, 2) contact with semen and vaginal secretions, or, 3) perinatal transmission, 
which is known as the period concentrated around the time of a child’s birth. Human CD4+ T-
cells and macrophages are the primary targets of the HIV-1 virus.  Once inside these cells, the 
virus begins replicating by using the host’s cellular mechanisms.  Once the viral RNA is released 
into the cell it is reverse transcribed into cDNA and ready for integration into the host’s DNA.  
This integrated form of the viral DNA is known as the provirus and once established, this DNA 
is permanently incorporated into the genome of the infected cell.  There is no known mechanism 
by which it can be efficiently eliminated (2).  From there, the proviral DNA is transcribed and 
RNA transcripts are transported out of the nucleus.  Subsequently viral proteins are synthesized 
in the cytoplasm and assembled into newly formed viral particles.  During its life cycle, the viral 
genome plays an important role in virus replication.  The genome of HIV-1 consists of both 
structural and enzymatic polyproteins (Gag, Pol, and, Env) and the two groups of 
regulatory/accessory proteins (Figure 1).  Tat and Rev comprise the first group and are described 
as the regulatory proteins.  The second group is referred to as the accessory proteins and is 
comprised of Nef, Vif, Vpu, and, Vpr (virology).  The regulatory proteins are essential for viral 
replication, whereas the accessory proteins aid in enhanced viral production.  
 
 
Figure 1: Schematic representation of HIV-1 Virus Genome 
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2.0  THE VIRAL PROTEIN R (VPR) GENE 
2.1.1 Structure of Vpr 
HIV-1 vpr is a well-conserved viral gene with an average length of 96 amino acids with a 
predicted molecular weight of 15kDa (4-7).  The gene is located in the central region of the HIV-
1 genome between vif and vpu overlapping vif at its 5’ end and tat at its 3’ end (8,7).   HIV-1 vpr 
is expressed as a late protein during virus replication.  A proposed tertiary structure of Vpr is 
based on a nuclear magnetic resonance (NMR) analysis which consists of three α-helical 
domains: an α-helix-turn-α-helix domain in the amino-terminal half from amino acids17 to 46 
and a long leucine rich α-helix from 53 to 78 in the carboxy-terminal half (4,6).  The three 
helices, which are connected by loops, are folded about a hydrophobic core surrounded by a 
flexible negatively charged N-terminal domain and a positively charged arginine-rich C-terminal 
region (7, 9).  The arginine-rich carboxy-terminus of vpr has similarities when compared to 
arginine-rich protein transduction domains, which may explain the transducing capabilities of 
Vpr including its ability to cross the cell membrane lipid bilayer (7, 10-13).  One side of the helix 
offers a stretch of hydrophobic residues that can form a leucine-zipper-like motif (14).  This 
motif may in fact account for the formation of Vpr dimers and/or for the interaction of Vpr with 
different cellular proteins (4, 15-20).  Both helical domains contribute to the incorporation of Vpr 
into virions, specifically through the interaction between Vpr and the p6 form of the viral 
protein, Gag (4).  Gag, the structural protein, forms the core, capsid and matrix of the virus 
particle. 
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2.1.2 Functional Analysis of HIV-1 Vpr 
Detailed analyses of vpr have concluded that the gene encodes for a protein that is involved in 
many functions during the life span of the virus.  Vpr is responsible for carrying out several 
functions including transactivation of the autologous HIV-1 promoter LTR as well as 
heterologous host cellular promoters, formation of ion selective channels in the lipid bilayers, 
and regulation of cellular apoptosis (4).  Vpr also aids the virus in fulfilling three major 
functions: (1) regulation of the nuclear transportation of the HIV-1 pre-integration complex 
(PIC), (2) virion incorporation of newly formed particles, and (3) induction of cell cycle arrest of 
the infected proliferating cells. 
Nondividing cells, such as resting T-cells and terminally differentiated macrophages, are 
important targets for viral replication during the initial stages of infection, since primary 
infection of these cell populations contributes to the establishment of viral reservoirs.  Such 
reservoirs are crucial for subsequent virus spread to the lymphoid organs and the T-helper 
lymphocytes (21).  After virus entry into the cell, the viral capsid is rapidly uncoated and the 
reverse transcription of the genomic HIV-1 RNA leading to the full-length double strand DNA is 
completed.  This viral DNA associates with viral and host cell proteins into the aforementioned 
PIC.  Lentiviruses are unique in the fact that they have evolved a strategy to import their own 
genome through the envelope of the interphasic nucleus via an active mechanism within four to 
six hours post infection (22).  Data has supported the notion that Vpr enhances the transportation 
of viral DNA into the nucleus of nondividing cells by promoting direct or indirect interactions 
with the cellular proteins, especially the nuclear importins, regulating the nucleo-cytoplasmic 
shuttling (23-30).  The exact composition of the PIC has yet to be determined, but what is known 
is that it is comprised of the viral DNA associated with integrase, cellular factors that participate 
in both intra-cytoplasmic routing and nuclear translocation of viral DNA, and, Vpr (31-33).  The 
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PIC progresses through the cytoplasm via the cytoplasmic dynein motor and travels along the 
microtubule network in order to migrate towards the nucleus.  The role of Vpr in association 
with the PIC is still unclear.  It is not yet known whether Vpr plays an active role during the 
movement of the PIC along the microtubules or whether it is only associated with the complex 
and then actively participates in the subsequent steps of anchoring the PIC to the nuclear 
envelope and the nuclear translocation of the viral DNA (7). 
Cells expressing Vpr have been known to accumulate in the G2/M phase of the cell cycle.  
It has been shown that Vpr targets a general host cellular mechanism that controls progression of 
cells from G2 to mitosis.  Briefly, in normal cells p34cdc2 is phosphorylated, which is one of the 
first steps in the transition phase from G2 to mitosis (4, 34).  However in Vpr-infected cells, 
p34cdc2 is for the most part inactive, leaving the cells suspended in a phase ideal for viral 
replication. The determinants of the G2 arrest activity are mainly located in the C-terminal 
unstructured basic region of HIV-1 Vpr and phosphorylation of Vpr protein is required for Vpr-
mediated cell cycle arrest (35, 36).   Several forms of Vpr, i.e. intracellular, intravirion, and free 
Vpr, present within the host are capable of inducing cell cycle arrest function upon exposure (5, 
37).  There are also several lines of evidence in support of the involvement of these various 
forms of Vpr in pathogenic events as well as in the regulation of HIV-1 replication (5). 
2.1.3 In vivo analysis of Vpr: Long-Term Nonprogressors (LTNPs) or Slow Progressors 
and Rapid Progressors (RPs) 
Earlier efforts in studying the role of vpr in HIV-1 disease progression were for the most part 
based on nucleotide sequence analysis (6).  This method proved very useful in detecting gene 
deletions, insertions, and, mutations. Even though the vpr sequence is one of the most conserved 
regions of the HIV-1 genome, variations are inevitably found in the quasispecies that affect 
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patients, ultimately affecting the rate of disease progression.  Thus the two category terms Long-
Term Nonprogressors (LTNPs) and Rapid Progressors (RPs) were devised in order to describe 
the progression of viral pathogenesis within the HIV-1 patient  (38, 39).  LTNPs are defined as 
asymptomatic with CD4 T-cell counts > 500 X 106 cells/1, low levels of spontaneous apoptosis, 
and low or undetectable viral loads for at least ten years.  They also maintain a strong immunity, 
both humoral and cellular, against HIV-1 without the assistance of any antiretrovirals such as 
HAART (8, 40, 41).  The RPs on the are symptomatic and progress to AIDS within the usual 
time span of ten years, without the help of antiretroviral therapy.  Recently, a non-functional 
mutation (R77Q) identified in vpr has been implicated in readily establishing long-term chronic 
infection of T-cells, whereas wild type vpr is known to increase the rate of viral replication and 
cytopathic effects of the virus in cell culture (42).  Specific mutations within the vpr gene include 
several known changes that seem to be associated with this slow progression to disease. 
Mutations within vpr include the polymorphism at the 3rd amino acid residue.  Normally 
at this position the presence of glutamine (Q) has been observed, however in LTNPs, it has been 
replaced by arginine, R.  This change has been shown to significantly impair the ability of Vpr to 
confer its normal cytopathicity.  But this polymorphism has no effect on the efficiency of the 
virus to replicate (6, 43).  Similarly the C-terminal domain mutant R80A is another mutation 
studied in this regard.  This particular mutation abolishes the G2/M cell cycle arrest which, as 
discussed earlier, the virus depends on to suspend cells in this specific transition phase, leading 
to an increase in viral replication (44). The next mutation in Vpr that has been studied is the 
R77Q mutation where an arginine (R) residue is replaced by a glutamine (Q) residue.  This point 
mutation does impair the capability of Vpr in inducing cellular apoptosis in the absence of cell 
cycle arrest, which could overall dramatically affect disease progression (8, 38, 45).  However, a 
recent study disputes this observation indicating that this change may not in fact be only 
associated with just the LTNPs, since it is also present in the RPs (45).  This suggests that R77Q 
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is just another point mutation and it may not be related to disease progression as thought earlier.  
Another mutation identified at the onset of HIV-1 research involved the deletion of vpr from the 
virus. The HIV-1 viral strain HxB2 carries this distinctive mutation that leads to the premature 
termination of the open reading frame (ORF), impairing the ability of Vpr to induce cell cycle 
arrest and apoptosis (6, 46).  More recently reviewed is the insertion of arginine (R) at position 
90 in the gene, which alters the highly conserved C-terminal motif.  The C-terminal motif, 
defined as RQRRAR, has previously been indicated as playing a role in nuclear localization as a 
nuclear localization signal (NLS) (15).  This motif is believed to play a role in subtype B Vpr 
nuclear targeting (15).  To date, subtype O is the only other subtype with the R insertion leaving 
the sequence with a consensus length of 100 amino acid residues in comparison to the usual 96 
amino acid residues.  Therefore, gene defects that diminish any of the Vpr-specific activities 
would have a negative impact on viral survival and thus could potentially slow down disease 
progression (16). 
Human leukocyte antigens (HLA) exist in large numbers within the human population.  
Their alternatives, HLA alleles, are known for their association with disease, some of which have 
the ability to increase the risk and progression of certain human diseases such as HIV-1 (41).  
Mutations are known to cluster in certain HLA regions, suggesting an HLA-driven evolution of 
the gene vpr.  Studies have documented that HLA-B27 and HLA-B57 as well as others are 
strongly associated with slower rates of disease progression, making them a protective agent in 
LTNPs.  Certain subtypes of the HLA alleles such as HLA-B35 and HLA-A29 are, however, 
known for being associated with faster rates of disease progression (47, 48).  These findings lead 
to the conclusion that Vpr protein evolution may in fact be host- driven (15). 
Within the last few years, research has been carried out to study the effects that antiretrovirals 
have on the HIV-1 viral strains within patients.  The results reported several HAART-induced 
mutations.  The mutation with the highest frequency was seen repeatedly in LTNPs on HARRT 
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and involves a serine (S) to asparagines (N) change at position 28 on the vpr.  To validate this 
particular polymorphism, gene analyses were performed and no other defects were found in any 
of the other HIV-1 genes, thus implying that this mutational change was in fact unique to the vpr 
gene (15). 
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3.0  PUBLIC HEALTH SIGNIFICANCE 
Human immunodeficiency virus (HIV) is still among the top killers of the world population.  
Throughout the world the virus is broken up into types, i.e. type 1 or type two, as well as 
different clades or subtypes, i.e. clade B in North America, clade C in India (49).  Based on the 
viral pathogenesis seen in vivo, the resulting disease has been divided into to very distinctive 
categories: Rapid Progressors (RPs) and Long Term Non-Progressors (LTNPs) (38, 50).  The 
difference between the two groups of patients is the time in which HIV develops into full-blown 
AIDS.  CD4+ T-cells and macrophages constitute the main cell targets of the virus.  Once inside 
these cells, the virus begins replicating by using the host’s cellular mechanisms. It is through 
these replicative stages that the virus makes changes in its own genome, resulting in the 
manufacturing of new/recombinant virus strains that are not only different from the original 
infecting virus, but also between each other.  Throughout its evolution HIV has developed ways 
to “outsmart” its hosts through techniques such as mutation and its ability to hide for months or 
even years at a time.  Understanding the pathogenesis and the strategies that are employed by the 
virus using its gene products such as Vpr is greatly needed to develop immune therapeutics and 
antivirals. Furthermore, lessons learned from in vivo analysis of the vpr gene and its role in 
disease status will lead to the identification of domains that play a role in host cellular 
alterations, thus new targets for therapeutic interventions.   
Most patients infected with HIV-1 develop AIDS unless they receive antivirals such as 
HAART.  The only hope in counteracting the effects of HIV is through the use of antiviral 
medications.  But studies have shown that not everyone has the same positive effect when these 
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drugs are administered.  With the new reports of “Super AIDS” in the media, the world is ready 
for a new approach to battling with this ultimately deadly disease (51).  With the development of 
a working vaccine, scientists hope to be able to lessen the effects that this virulent virus has had 
on the human population as a whole. 
The public health significance of this project is to provide valuable research that will lead 
towards such a viable HIV-1 vaccine for the general population.  By studying the individual 
genes of the virus, researchers will be able to better understand the mechanisms by which such a 
complex virus operates.  In the history of sexually transmitted diseases, no one has been able to 
develop a means of eradication, ever.  This work, which entails detailed research into the many 
different aspects of the HIV-1 viral gene vpr, encompasses the very beginning stages of vaccine 
development and of hope for such a cure. 
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4.0  THESIS AIMS 
The HIV-1 genome in infected individuals demonstrates a marked heterogeneity.  Even within a 
single infected individual, the virus exists as quasispecies.  The HIV-1 genome codes for the 
three structural/enzymatic genes Gag, Pol, and, Env, the two regulatory genes Tat and Rev, and, 
the four accessory genes vif, nef, vpu, and, vpr.  In addition to their roles in viral replication and 
pathogenesis, expression of these accessory genes has been implicated in modulation of host 
cellular events.  The vpr gene specifically is known to modulate a number of host cellular events, 
however, it is unknown how the Vpr-mediated cellular events affect viral pathogenesis and 
disease progression. 
HIV-1 patients harbor distinct genotypes and phenotypes of the accessory gene products 
at various stages of infection, suggesting a correlation between genotypes and disease 
progression.  Using a longitudinal cohort of HIV-1 patient samples, I propose to functionally 
characterize the Vpr genotypes associated with disease progression.  By characterizing Vpr 
within the individual, naturally occurring mutations and deletions within Vpr can be reviewed to 
determine if the protein is in fact lethal or defective and further correlate this with disease 
progression and clinical outcome.  This knowledge will also help in future studies involving 
HIV-1 vaccine development. 
4.1.1 Specific Aim #1 
Isolation of vpr from samples of HIV-1 infected individuals within the cohort study. 
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A) DNA Extraction 
B) Vpr Amplification 
4.1.2 Specific Aim #2 
Genotyping analysis of Vpr from patient samples. 
A) Vpr Cloning and Screening 
B) Patient Sequence Analysis 
C) Phylogenic Tree Composition 
D) Reporter Assay and Protein Quantification 
5.0  MATERIALS AND METHODS 
The patient population used in this study is part of the Multicenter AIDS study  (MACS) group. 
Using appropriate protocols and IRB approval, samples were received from Baltimore and 
Northwestern as part of the MACS. Frozen peripheral blood mononuclear cells (PBMCs) were 
shipped to us in dry ice and the samples were stored at –20˚C before further use. 
 
 
Table 1: Demographic information and disease status of the MACS patient population used in this study. 
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5.1 DNA EXTRACTION 
Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs) from each of 
the eleven patients, courtesy of the Multicenter AIDS Cohort Study (MACS) (Table 1).  The 
PBMCs were obtained from the Northwestern University, IL and John Hopkins University, 
Baltimore MACS facilities.  The DNA extraction was carried out using the GFX Genomic Blood 
DNA Purification Kit (Amersham Pharmacia Biotech Inc, Piscataway, NJ) for each of the 
MACS patients.  Briefly, PBMC pellets were allowed to thaw at room temperature after being 
removed from -80°C. Extraction Solution (500 µl) was added to the cells and immediately 
vortexed before allowing the mixture to incubate for five minutes at room temperature.  The cells 
and extraction solution were placed inside a GFX column, and was centrifuged for one minute at 
8,000 rpm.  The flow-through was discarded, 400μl additional Extraction Solution was added to 
the column, and spun for another minute at 8,000 rpm.  After discarding the flow-through, 500μl 
of the Wash Solution was added to the column.  The column was spun for three minutes at 8,000 
rpm and the flow-through was discarded.  The tube was spun a final time to ensure that all of the 
lysate was removed and only the genomic DNA remained bound to the column.  Next the GFX 
column was placed into a new microcentrifuge tube and 200μl of autoclave water (pre-heated to 
70°C) was added into the column.  The column was incubated for one minute at room 
temperature before being spun at 8,000 rpm for one minute.  In order to make sure the new tubes 
now contained the recovered purified genomic DNA to be used throughout the experiments, 10μl 
from each sample was run on a 1% agarose gel (0.60g Agarose Low EEO heated with 1X TBE 
solution). 
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5.2 VPR AMPLIFICATION 
The genomic DNA extracted from the PBMCs contains copies of the full length HIV-1 viral 
genome.  In order to clone vpr, polymerase chain reaction (PCR) was required for its 
amplification.  The vpr primers used for PCR corresponded specifically to nucleotides of the 
pNL43 HIV-1 proviral genomic sequence and contained both an  external vpr primer, including 
approximately an additional one hundred base pairs upstream and downstream of the actual gene, 
and an internal vpr primers, containing approximately ten additional base pairs upstream and 
downstream of the gene (Table 2).  The later is thought to be more conventional for future 
functional studies. 
 
 
Table 2: List of the primers used for amplification of vpr during pcr. 
Forward 5’ GAC GGA CAT AAC AAG GTA GGA 3’ Vpr 
(external) 
Reverse 5’ GTC GCT GTC TCC GCT TC 3’ 
   
Forward 5’ AGG ACA GAT GGA ACA AGC CCC AGA AGA CCA AG 3’Vpr 
(internal) Reverse 5’ CTA GGA TCT ACT GGC TCC ATT TCT TGC TCT 3’ 
 
 
 
 
The PCR protocol used is as follows, starting with the PCR reaction samples and ending with the 
thermocycler conditions:  35μl of autoclaved water, 5μl of 10X buffer, 2μl of dNTPs, 5μl of 
genomic DNA, 1μl of the forward primer (10pmol/μl), 1μl of the reverse primer (10pmol/μl), 
and, 1μl Taq Polymerase were added sequentially to a PCR grade microcentrifuge tube for a 
final solution volume of 50μl for each patient.  The tubes were then run under the PCR 
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conditions of 95°C for two minutes, 30 cycles of denaturing at 95°C for one minute, annealing at 
54°C for one minute, extension at 72°C for two minutes, and a final elongation time of 72°C for 
fifteen minutes.  10μl of the finished amplified product was run on a 1% agarose gel for the 
identification of the vpr fragment.  The protocol for internal Vpr (Vpri) has only one difference; 
the PCR reaction sample requires the use of 10μl of genomic DNA.  The PCR conditions are as 
follows: 95°C for two minutes, 45 cycles of denaturing at 95°C for one minute, annealing at 
60°C for one minute, extension at 72°C for two minutes, and, a final elongation time of 72°C for 
fifteen minutes.  To verify this smaller fragment, 10μl of the finished amplified product was run 
on a 2% agarose gel (1.20g Agarose Low EEO heated with 1X TBE solution). 
5.3 VPR CLONING AND SCREENING 
5.3.1 Vpr Cloning 
After the PCR products were verified to be that of vpr based on the amplified fragment size by 
electrophoresis, the next step was to incorporate the gene into an expression vector to conduct 
further gene function analyses.  Vpr was cloned in to pcDNA3.1/V5-His TOPO-TA vector using 
the Cloning/Expression Kit (InVitrogen, Carlsbad, CA) according to the manufacturers’ 
instruction.  Each sample was ligated with the vector and transformed into E. coli bacteria in 
order to produce clones for study purposes.  The cloning procedures are as follows: 8μl of the 
PCR product, 1μl of the provided Salt Solution, and, 1μl of the TOPO vector were combined in a 
microcentrifuge tube, mixed gently, and allowed to incubate at room temperature for thirty 
minutes.  5μl of the incubated TOPO Cloning Reaction was added to a tube of competent E. coli 
cells that were provided with the cloning kit.  The tube was mixed gently and allowed to incubate 
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on ice for another thirty minutes.  Next the tube was heat-shocked in 42°C water for 45 seconds, 
then returned back to the ice for two minutes.  450μl of media was combined with the contents of 
the tube into a new inoculation tube and shook at 197 rpm for 2 hrs.  Different quantities (100 
and 200 µl) of the transformed samples were spread over an ampicillin-containing Luria Bertani 
(LB) agar plate in order to allow for optimal colony growth.  Plasmid DNA was isolated by lysis 
boiling prep.  Briefly, individual colonies were collected and grown overnight in 4mL LB with 
ampicillin (100mg/mL). Cells were spun down (10,000 rpm for five minutes) and cell pellets 
were lysed using a combination of 450μl of STET buffer and 25μl of lysozyme.  Cell lysate was 
vortexed and placed in a boiling bath for approximately one minute before being spun down at 
13,000 rpm for ten minutes.  After the newly formed debris pellet was removed from the 
supernatant, 25μl of sodium acetate and 250μl of 2-propanol were added and the solution 
incubated at room temperature for 30 minutes.  Following incubation the solution was spun 
down at 13,000 rpm for ten minutes, washed with 70% cold ethanol, and, spun down using the 
aforementioned parameters.  The supernatant was decanted and the DNA pellet was allowed to 
dry completely at 37°C before dissolving in 50μl of TE buffer. 
5.3.2 Vpr Screening 
The screening of individual colonies involved the restriction digestion of the purified plasmid 
DNA.  The enzymes used in the restriction digest were EcoRI, HindIII, and, XhoI (New England 
Biolabs, Beverly, MA).  The first digestion used HindIII and XhoI to release the vpr DNA 
fragment from the plasmid TOPO vector and HindIII and EcoRI were used in the second 
digestion as a means to verify the orientation of the cloned vpr gene.  All positive colonies were 
used to prepare clean DNA for sequencing using the QIAprep Miniprep kit (QIAGEN, Valencia, 
CA) and quantitated by spectrophotometer. Sequencing of the positive colonies was performed at 
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the University of Pittsburgh Genomics and Proteomics Core Laboratory.  All sequences were 
verified using forward and reverse primers to confirm any changes. 
5.3.3 Nucleotide Sequence Analysis 
Based on the nucleotide sequences obtained from the core facility, the sequences were subjected 
to a number of analyses.  First, sequences were loaded into the Edit Sequence program for the 
purpose of determining the chromatography of the individual sequences.  Within this particular 
program adjustments could be made to any nucleotide residues not properly read by the 
Genomics and Proteomics Core Laboratory.  This procedure usually involved changing N’s to 
one of the corresponding four-nucleotide base pairs: adenine (A), thymine (T), guanine (G), or 
cytosine (C), as well as deleting any bases that did not contain an actual peak on the 
chromatogram.  From here the sequences were read into the DNA Strider program for vpr 
verification.  If DNA Strider could not verify the presence of vpr, the sequence was blasted using 
the public National Center for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/) to search for any sequence homology with the pNL43HIV-1 
proviral sequence (Los Almos National Library) vpr gene.  After gene verification the newly 
derived vpr sequences were loaded into the ReadSeq program 
(http://bimas.dcrt.nih.gov/molbio/readseq) and converted into the FASTA format for easy 
reading by other sequence analysis programs.  Finally the sequences, along with the HIV-1 
pNL43-Vpr sequence, were downloaded into the Clustal W online program 
(http://www.ebi.ac.uk/clustalw/), which allowed for sequence alignment and phylogenic tree 
analysis. 
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5.4 CELL CULTURE 
5.4.1 Primary Cell Line 
HeLa cells used for transfection were obtained from the NIH AIDS Research and Reference 
Program (ARRRP).  HeLa cells were cultured in Dulbecco’s modified Eagle medium (DMEM), 
supplemented with 10% heat inactivated fetal bovine serum (FBS) (Cambrex, Walkersville, MD) 
and 1% penicillin-streptomycin (GIBCO, Grand-Island, NY).  The cells were then maintained in 
a 37°C humidified chamber at 5% CO2. 
5.4.2 Transfection 
HeLa cells were transfected with 0.5μg of Vpr expression plasmid  and the HIV-1 LTR with a 
luciferase reporter gene using Lipofectamine 2000 reagent (InVitrogen, CA).  When applicable 
mutated Vpr clones were utilized for the transfections, specifically clones from different MACS 
patients as shown in Table 3.  Both the lipofectamine and the HIV-1 LTR with luciferase were 
diluted into OPTI-MEM (GIBCO) prior to being added to the HeLa cells.  After an incubation 
time of 3 hours at 37°C, 5% CO2, the cells were washed and DMEM was added for an additional 
incubation time of 48 hours at 37°C, 5% CO2.  1X Repoter Lysis Buffer was used to lyse the 
cells following transfection. Cell lysates were spun at 12,000 rpm at 4˚C to remove cell debris 
and cell lysates were used to measure the luciferase activity.  Protein concentration in cell lysates 
were measured and normalized with the luciferase activity. 
 
 
 
 
 
  
 
Table 3: HeLa Cell Transfection Data.  Clones used from MACS and PittMen Study for transfection 
analyses. 
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6.0  RESULTS 
6.1 SPECIFIC AIM #1: ISOLATION OF VPR FROM SAMPLES OF HIV-1 
INFECTED INDIVIDUALS WITHIN THE COHORT STUDY 
6.1.1 Genomic DNA preparation 
The HIV-1 positive patients within the MACS group were infected with the viral strain from 
clade B, which is found primarily within North America.  Genomic DNA was obtained from the 
PBMC cell pellets using the GFX Genomic Blood DNA Purification kit (Amersham Pharmacia 
Biotech Inc, Piscataway, NJ).  The resulting solutions from each patient were run on an agarose 
gel to ensure that DNA had been extracted from the PBMCs (Figure 2).  A total of eleven patient 
PBMCs were successfully extracted from the cell pellets.  To ensure that patient samples were 
not contaminated or mislabeled, no more than four samples were used at a given time.  The 
working patient samples of genomic DNA were kept in 4°C for future use with PCR. 
 
 
 Figure 2: Electrophoretic analysis of genomic DNA.  After the extraction from the MACS patient 
PBMC cell pellets, samples were run on a 1% agarose gel to confirm the extraction of genomic DNA.  Lane 
assignments: 1) PT176 2) PT330 3) PT109 4) PT007. 
 
6.1.2 PCR Amplification 
The patient samples contain few copies of the integrated proviral DNA therefore a nested PCR 
amplification step was necessary to amplify the viral gene products.  This includes both single 
round as well as multiple rounds of PCR amplification steps. For the first round of PCR, external 
primers were used (primers designed 110 base pairs before the start codon of Vpr as well as 128 
base pairs beyond the stop codon of Vpr) to amplify a 446 bp fragment. First, patient samples 
were processed through a round of PCR to amplify the vpr gene and run on an agarose gel 
(Figure 3A).  The presence of a band approximately 446 base pairs verified that vpr had been 
amplified from the patient genomic DNA.  After verification, the second round of PCR was 
performed using internal primers amplified the vpr gene, ORF of 299 bp.  This second round of 
amplification used genomic DNA from the first round PCR instead of the working patient 
samples of genomic DNA as a template. This particular PCR produced a band that was 
approximately 299 base pairs in length (Fig. 3B). 
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 Figure 3: PCR of Vpre and Vpri.  Following the PCR amplification of vpr, the PCR products were run on a 
1% agarose gel to confirm the size of the fragments.  (A) The first round of PCR indicating the external vpr 
fragments approximately 446 bp.  Lane assignments: 1) PT 330 2) PT007 3) PT3028 4) PT9831 5) PT3827 6) 
PT7329 7) PT1629 8) PT5731 9) Marker.  (B) The second round of PCR indicating the internal vpr fragments 
approximately 299 bp. Lane assignments: 1) PT 330 2) PT007 3) PT3028 4) PT9831 5) Marker 6) PT3827 7) 
PT7329 8) PT1629 9) PT5731. 
 
6.2 SPECIFIC AIM #2: GENOTYPING ANALYSIS OF VPR FROM PATIENT 
SAMPLES 
6.2.1 Cloning and screening of the vpr gene 
In order to further our knowledge on the aspects of the individual gene functions, the 
amplified vpr gene fragments needed to be incorporated into a eukaryotic expression vector.  The 
vpr gene fragments were ligated into a pcDNA3.1/V5-His/TOPO TA cloning expression vector 
(InVitrogen, CA) with the His tag attached to its C-terminus.  This particular vector construct 
also includes a T nucleotide overhang, which is specific to the A nucleotide overhang provided 
by Taq-amplified PCR products for cloning purposes.  The ligation reaction was transformed 
into the competent E. coli cells and plated on an ampicillin containing LB plate and incubated at 
37˚C overnight. Colonies were selected and grown in LB media for further screening. Patient 
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samples were screened using two sets of double digestion incorporating twelve colonies.  The 
first digestion consisted of a HindIII and XhoI reaction, which released the vpr gene fragment 
from the vector.  Out of the first screening of twelve colonies I averaged between six to eight 
positive clones, the second screening of colonies averaged seven positive clones.  The sole 
purpose of the second digestion, which involved a HindIII and EcoRI reaction, was to confirm 
the orientation of the vpr fragment inside the vector. The clones, which released the right sized 
fragment on the agarose gel, were used to prepare clean DNA for the sequencing analysis (Figure 
4). 
 
 
Figure 4: Electrophoretic analysis of vpr cloning by restriction digest.  Patient clones were screened in order 
to verify the presence of the ligated vpr fragment into the pcDNA3.1 vector through plasmid digestion using 
HindIII and XhoI. 
 
 
6.2.2 Patient sequence analysis 
All of the positive clones from the eleven MACS patients were sent off to the University 
of Pittsburgh Genomics and Proteomics Core Laboratory for sequencing. Results from the 
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sequence analysis were verified and subjected to several analysis programs.  Verification of the 
sequences was obtained by using the program methods of Edit View, DNA Strider, and, NCBI as 
described earlier.  Briefly, the sequences were loaded into the Edit Sequence program for the 
purpose of determining the chromatography of the individual sequences.  Within the program 
nucleotide residues could be adjusted for peak positions not previously read by the Core Lab.  
The sequences were then read into the DNA Strider program for vpr verification.  If however the 
program could not identify vpr, a gene blast was performed using the NCBI database.  The 
database compared the MACS patient sequences to that of the pNL43 HIV-1 proviral sequence 
vpr gene.  After vpr confirmation, the sequences were read into the ReadSeq program and 
converted into the FASTA format before being downloaded into the Clustal W online program.  
The Clustal W program produced sequence alignments and the formation of phylogenic trees, 
which allowed for further analysis of the patient sequences. 
Since all of the MACS patients are from North America (possible clade B), Vpr from the 
pNL43 HIV-1 proviral sequence was utilized for the consensus. Within each patient, the 
individual sequences were analyzed for the different variations observed in order to determine 
the interpatient variation, while keeping in mind that all of the analyses were based on the 
deduced amino acid sequences and that any of the change variations observed within a 
nucleotide could be silent and/or nonsense which would result in no significant changes within 
the amino acid or the protein composition.   
Comparisons of the deduced amino acid sequences (A) and their respective phylogenetic tree 
analysis (B) for all eleven MACS patients are shown in figures 5–15.  In general the sequences 
within theses patients are conserved. These results are very similar to the published reports 
indicating that accessory genes are more conserved than the structural proteins Env and Gag 
(52).  Sequence analysis of patient #1 (PT1) indicates that this patient exhibits two major variants 
within the vpr alleles (Figure 5A). Interestingly most of the mutations occur within a particular 
 27 
residue.  For examples the observed mutations in PT1 are at amino acid positions 11, 28, 41, 77, 
and, 83. At position 11, glutamine (Q) is mutated to either serine (S) or alanine (A), whereas N41 
is mutated to serine (S), where S has a role in protein phosphorylation.  The most interesting 
genotype of PT1 is the presence of R77Q. Previous studies have demonstrated that R77Q is 
involved in LTNPs phenotype (8).  Given the fact that many of these patients are LTNP, this 
observation directly correlates with the functional phenotype of Vpr in disease progression. 
  
 
 
Figure 5: MACS patient #1 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of the 
patient variants. 
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Using the deduced amino acid sequences, a phylogenetic tree was generated that grouped these 
sequences into variants (Figure 5B).  The phylogram also shows that vpr clones 2, 3, 4 and, 5 
share  similar homology within them, while the other alleles are grouped into two other branches. 
Similar analyses were performed for all of the MACS patients.  Patient #2 (PT2) , showed higher 
mutation rates as well as multiple quasispecies (Fig. 6A &B).  The mutations observed are at 
amino acid residues 19, 28, 37,41, 45, 64, 83, 85, and, 86.  As seen in PT1 S28 and N41 have 
been mutated, but in PT2 the amino acids are mutated to asparagine (N) and glycine (G), 
respectively.  The mutations observed are highly conserved in the fact that when a mutation does 
occur, it is the same for all of the alleles.  This is evident in the constructed phylogram, which 
shows three very distinct branched groups.  Only three of the vpr alleles from patient #3 (PT3) 
(Figure 7A) were observed to have mutations.  For allele #1 the mutation occurs at the end of the 
sequence starting with the amino acid, which corresponds to position 88.  For allele #7 the 
mutation occurs at amino acid position 80, but instead of the R80A mutation, this one converts to 
lysine (K).  The most unique allele from PT3 is #3, which has mutations located at aspartic acid 
(D) 7 glutamic acid (E) and tyrosine (Y) 15 histidine (H).  But what makes this allele unique is 
that fact that an isoleucine (I) is inserted into the sequence between amino acid positions 26 and 
27.  As for the phylogram, Figure 7B shows that all of PT3’s alleles are located on different 
branches. Figure 8A depicts the observed mutations for patient #4 (PT4), which can be seen at 
amino acid positions 37, 40, 41, 83, 84, and, 85.  The corresponding mutations for those 
mutations are isoleucine (I) to threonine (T) and glutamic acid (E), histidine (H) to glutamine 
(Q), asparagine (N) to serine (S) and glycine (G), valine (V) to isoleucine (I), threonine (T) to 
isoleucine (I), and, arginnie (R) to proline (P).  The generated phylogenetic tree for PT4 (Figure 
8B) is grouped into four distinct branches.  Patient #5 (PT5) is the only patient in which all of  
 
  
 
 
 
Figure 6: MACS patient #2 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of the 
patient variants. 
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Figure 7: MACS patient #3 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of the 
patient variants. 
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Figure 8: MACS patient #4 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of the 
patient variants. 
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the deduced vpr alleles match up precisely with the pNL43 consensus sequence.  This is evident 
in both figures 9A and B due to the lack of observed mutations and multiple grouped branching.  
Two of the amino acid sequences from patient #6 (PT6) are exactly identical to the pNL43 
consensus sequence, while the other two contain mutations, but in different spots, all of which 
can be seen in (Figures 10A and B).  The mutation observed in allele #4 constitutes a change 
starting at amino acid position 66.  Allele #3 has a mutation at amino acid positions 45, 77, 83, 
84, 86, and 87.  However the mutation that stands out the most is the R77Q amino acid change, 
which  has been linked to the LTNPs phenotype. The mutations observed in patient #7 (PT7), 
figure 11A, are seen at amino acid positions 15, 20, 28, 33,37,41, 77, 83, and, 87.  S41N and 
R77Q are the main mutations that seem to be showing up more frequently throughout the 
previous patient sequences.  Figure 11B shows that PT7’s sequences are grouped into two main 
branches, with two subdivisions, which strongly suggest the similarities between alleles 4-6.  The 
amino acid sequences deduced from patient #8 (PT8) are comprised of two alleles that have the 
R80A mutation, which are shown in figure 12 A.  Also shown within the same two alleles are the 
mutations that have previously been identified as V83I, T84I, and R85Q.  The last allele has 
been mutated at the end of the sequence, starting with amino acid position 82.  Figure 12 B 
shows the groupings of the branches for the individual alleles.  For example alleles 4 and 5 are 
identical to the pNL43 consensus, and thus are grouped together on the same branch, as are 
alleles 1 and two, which possess the same multiple mutations.  Patient #9 (PT9) possess the 
V83I, T84I, and R85Q mutation set and the 20, 28, 33,37,41 mutation set (Figure 13A).  PT9 
also has includes four alleles with the R77Q mutation as well as six different alleles, which 
contain the R80A mutation.  Allele #10 (R77Q) also contains and ending mutation that begins at 
amino acid position 91.  Within the phylogenetic tree (figure 13B) only five of the R80A alleles  
  
 
 
Figure 9: MACS patient #5 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of the 
patient variants. 
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Figure 10: MACS patient #6 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of 
the patient variants. 
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Figure 11: MACS patient #7 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of 
the patient variants. 
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Figure 12: MACS patient #8 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of 
the patient variants. 
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are grouped together off of the main branch of the tree, suggesting a strong variation between the 
sixth allele.  The mutations observed within patient #10 (PT10) are mainly comprised of V83I, 
The mutations observed within patient #10 (PT10) are mainly comprised of V83I, T84I, and 
R85Q mutation set as well as the 20, 28, 33,37,41 mutation set.  The allele with the latter 
mutation set also exhibits the R77Q mutation (Figure 14A).  The phylogram in figure14B shows 
that for the most part the sequences are conserved, due to the lack of multiple grouped branches.  
The deduced amino acid sequences from patient #11 (PT11) are highly conserved and are 
identical to the pNL43 consensus sequence, except for the amino acids starting at position 70 
(Figure 15A).  Alleles #9-11contain the mutation isoleucine (I) to leucine (L)  and a truncation of 
the sequence, while alleles #7 and #8 have a mutated sequence end beginning at amino acid 
position 82.  Alleles #5 and #6 contain the R80A mutation as well as the V83I, T84I, and R85Q 
mutation set.  Figure 15B shows a nice representation of PT11’s sequences with grouping and 
branching corresponding to the various observed mutations. 
  
 
 
 
Figure 13: MACS patient #9 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of 
the patient variants. 
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Figure 14: MACS patient #10 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of 
the patient variants. 
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Figure 15: MACS patient #11 analysis.  (A) Deduced amino acid variant sequences.  (B) Phylogenetic tree of 
the patient variants. 
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6.2.3 Phylogenic Tree Composition 
Additionally, using the sequences of all the patients used in this study, a Neighbor-Joining tree 
was generated in order to identify the variation within these patients (Figure 16).  Results 
indicate that certain patient variants are closely related, while the rest of the patients have 
variants within themselves, which are not similar to each other, which can been seen based on 
the groupings of the various branches produced.  Patients #1,4, and, 9 are grouped in a very 
similar way that is reflected by their individual trees (Figures 5B, 8B, and, 13B).  Patients #5 and 
6 are closely related to their earlier trees with the exception of one outlier (Figures 9B and 10B).  
Patient #7 is grouped in a way that makes the branching almost opposite that of its individual 
tree (Figure 11B).  Patients #2, 3, 8, 10, and 11 show no similarities to their individual trees 
(Figures 6B, 7B, 12B, 14B, and, 15B).  Overall, the Neighbor-Joining tree supports reported 
studies that indicate vpr as having a well-conserved genome (52). 
 Figure 16: Phylogentic tree comparison.  Comparison of all of the deduced amino acid sequences from the 
MACS patients with the consensus. 
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6.2.4 Reporter Assay and Protein Quantification: Correlation of biological function with 
the sequence variation of vpr alleles from patients 
HIV-1 Vpr is known to transactivate the HIV-1 LTR and increase virus transcription and 
replication.  To correlate whether these sequence variations have any biological functions, HeLa 
cells were transfected with the HIV-1 LTR luciferase and HIV-1 vpr from patients.  
Transactivation was measured using the RLU of vector transfected cells as 0 or the basal level 
activity.  Vpr specific transactivation of the HIV-1 LTR was calculated and the increase in log 
activity is presented in Figure 17.  Results indicate that vpr alleles, which exhibited the largest 
increase of transfection were comprised of deduced amino acid sequences similar to that of the 
vpr wild type virus.  Patients #5, 8, 10, and, 11 had sequences that were homologous to the 
consensus sequence, which in turn yielded transfections between 1.5 and 3.0 fold above the basal 
level.  PTs#7 and 11 were observed as having the same fold of approximately 3.0.  PTs #3 and 
14 were observed as being the only two alleles that had a transfection fold of greater than 10, 
which is interesting due to the fact that PT7 was homologous to pNL43, whereas PT11 exhibited 
both the R77Q and the Q3R mutations.  Overall, these findings show that the clones derived 
from each of the MACS patients are in fact potentially infectious and have the capability of 
expression in vivo. 
 
 
Figure 17: Log graph.  Transfection data of the MACS patient and PittMen Study vpr alleles. 
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7.0  DISCUSSION 
The HIV-1 vpr gene encodes a protein of 96 amino acids with a predicted molecular weight of 
15 kDa, and is relatively conserved in HIV and SIV (4, 5, 6, 7, 16, 53, 54). The vpr gene is 
dispensable for viral replication in T-cell lines and activated peripheral blood mononuclear cells 
(PBMC) in vitro (44).  Analyses of HIV-1 accessory genes (including vpr) in long-term 
nonprogressors (LTNP) and asymptomatic patients suggest that defects in accessory genes are 
related to LTNP.  The presence of defective or mutated vpr quasispecies has been associated 
with long-term nonprogressive mothers (4, 55).  Also, other studies have suggested that 
maintenance and selection for an intact vpr gene occurs in vivo (55, 56).  To test the role of Vpr 
in vivo, several studies were performed using a simian immunodeficiency virus (SIV) model.  
Members of HIV-2 and SIV, in addition to vpr, also contain vpx, a duplication of vpr (57).  In 
vitro studies have demonstrated that mutations in vpx can result in loss of infectivity of macaque 
macrophages (58).  Macaques infected with SIVmac239 containing a mutation in the Vpr 
initiation codon methionine (M) progressed to AIDS at a slower rate than those infected with 
wild type virus.  Though vpr is selected against in tissue culture, selection for Vpr function in 
vivo occurs in both humans and chimpanzees infected with HIV-1, suggesting that vpr employs a 
novel mechanism for maximizing virus production and pathogenesis in vivo (58).  More recently, 
several studies have linked the attenuated nature of Vpr in vivo and loss of T cell cytopathicity in 
HIV-1 infected patients (38, 43).  Transgenic mice expressing Vpr in the absence of other viral 
proteins further confirmed these findings, directly linking the cytopathic nature of Vpr and loss 
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of T cell loss in vivo (59, 60).  These observations suggest an important role for Vpr in vivo viral 
pathogenesis and disease progression. 
HIV-1 Vpr is present in detectable levels in the virus particle, making it one of the first 
HIV proteins seen by the host cell (38).  There are many diverse sources of Vpr available within 
the infected population.  Upon infection of cells by HIV-1, Vpr is synthesized as a late protein 
along with the structural proteins.  The protein is also associated with virus particles, which 
enables the virus particles to bring Vpr into the cells upon infection.  In addition to these 
infectious particles, there is also an abundance of non-infectious particles (on the order of 
1:50,000-1:100,000 infectious versus non-infectious), which also contain Vpr.  Hence, non-
infectious virions could also transfer Vpr protein into cells through endocytosis (61, 62).  It has 
been suggested that the free Vpr may be the result of Vpr released from infected cells as well as 
from lysis of virus particles.  The intrinsic ability of Vpr to traverse through the cell membrane, 
as demonstrated recently by several groups (10, 11, 63), provides another avenue by which Vpr 
released from the infected cells could influence the uninfected, but exposed bystander 
population.  It is widely accepted that Vpr has a role in cell cycle arrest and apoptosis 
(independent of cell cycle arrest) of primary cells and several cell lines (44, 64), however the role 
of cellular proteins involved in this are not known.  Vpr is known to activate several caspases 3, 
8, and, 9 as well as the mitochondrial membrane potential, indicating that several apoptotic 
pathways could be triggered by Vpr either simultaneously and/or sequentially (44, 65).  The 
important observation from these studies is that Vpr either directly and/or indirectly induces 
apoptosis in cells that are exposed to this protein, resulting in the possible induction of bystander 
cell death in vivo.  The results observed in this study also support this hypothesis. 
The capability of HIV-1 Vpr to directly affect the host’s cellular functions depends very much on 
its ability to maintain the highly conserved regions conserved.  Vpr, for the most part, is able to 
preserve itself and still accomplish all of its functions.  However, during the replicative cycles 
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alterations are made and mutations as well as truncations are introduced into the vpr geneome.  It 
is these alterations or mistakes that ultimately lead towards the adjustment of otherwise normal 
functions.  The one mutation that was observed the most within this particular population of 
MACS was the R77Q mutation.  This mutation was precisely shown to impair the ability of Vpr 
to induce cellular apoptosis.  And recent studies have also shown this point mutation to occur 
specifically within the HIV-1 population identified as LTNPs (8, 38, 45).  The results presented 
in this report support this theory as well as another current finding that the correlation between 
R77Q and LTNPs is not that biologically relevant (15).  Of the eleven patient sequences 
analyzed, Figure 18 illustrates the five patients (PT1, PT6, PT7, PT9, and, PT10) that showed the 
mutation incorporated into the viral genome.  The reason that these results are able to support 
both of the Vpr studies is by the simple fact that all but one of the MACS patients has been 
identified as a LTNP.  And the one patient (PT11) that still remains undetermined does not 
exhibit the R77Q mutation in any of its deduced amino acid sequences.  The recently deduced 
amino acid sequences of the patients also reveled the R80A mutation in a total of three patients; 
PT8, PT9, and, PT11.  The virus depends on the suspension of cells in the transition phase for 
replication.  R80A abolishes the ability of this function for the virus, ultimately decreasing the 
amount of viral replication.  Which is very interesting when considering that the only patient not 
identified as a LTNP possesses this particular mutation.  Another interesting observation 
revolves around the fact that PT9’s deduced amino acid sequences posses both R77Q and R80A, 
but not within the same qusiaspecies. Half of the the variants maintained the R77Q change, while 
the other half has maintained the latter. 
1                          28          40                   60                 80          
PNL43-Con
PT 1 MEQAPEDQGPQREPYNEWTLELLEELKSEAVRHFPRIWLHNLGQHIYETYGDTWAGVEAIIRILQQLLFIHFRIGCRHSRIGVTRQRRARN
2 ----------S----------------T------------S-----------------------------------Q-----I--------
3 ----------S----------------T------------S-----------------------------------Q-----I--------
4 ----------S----------------T------------S-----------------------------------Q-----I--------
5 ----------S----------------T------------S-----------------------------------Q-----I--------
6 ----------S-------------------------V---S---------------------T-------------Q-----I--------
7 ----------A-----------------------------S--------------------------------------------------
8 ----------A-----------------------------S-----------------------------------Q-----I--------
9 ----------A-----------------------------S-R---------------------------------Q-----I--------
10 ----------A-----------------------------S-----------------------------------Q-----I--------
PT 6
1 -------------------------------------------------------------------------------------------
2 -------------------------------------------------------------------------------------------
3 --------------------------------------------Y-------------------------------Q-----II-RN----
4 -----------------------------------------------------------------HTAVYP-..................Q
PT 7
1 ---------------D--------------------V------------------------------------------------------
2 -------------------------------------------------------------------------------------------
3 --------------F----I-----------------------------------------------------------------------
4 --------------F----I-------N----R---E---G-----------------------------------Q-----I---T----
5 --------------F----I-------N----R---E---G-----------------------------------Q-----I---T----
6 --------------F----I-------N----R---K---G-----------------------------------Q-----I---T----
PT 9
1 -------------------------------------------------------------------------------A--IIQ------
2 -------------------------------------------------------------------------------A--IIQ------
3 -------------------------------------------------------------------------------A--IIQ------
4 -------------------------------------------------------------------------------A--IIQ------
5 -------------------------------------------------------------------------------A--IIQ------
6 ----------------------------------------------------------------------------Q-----I---T----
7 --------------F----I-------N----R---E---G-----------------------------------Q-----I---T----
8 --------------F----I-------N----R---E---G-----------------------------------Q-----I---T----
9 --------------F----I-------N----R---E---G----------------K------------------Q-----T---T----
10 --------------F----I-------N----R---E---G--------------------------------------A--IIQ-T---M
PT 10
1 ----------------------------------------------------------------------------------IIQ------ÉÉÉÉÉ*
2 ------------------A---------------------------------------------------------------IIQ------
3 ----------------------------------------------------------------------------------IIQ------
4 ----------------------------------------------------------------------------------IIQ------
5 ----------------------------------------------------------------------------------IIQ------
6 -------------------------------------------------------------------------------------------
7 --------------F----I-------N----R-------G-----------------------------------Q-----I-------- 
 
 
 
 
Figure 18: Patient #1, #6, #7, #9, and, #10 deduced amino acid variant sequences exhibiting the R77Q 
mutation. 
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Once the amino acid sequences were derived, the next step was to perform relevant 
functional studies.  The functional analysis would in turn be able to identify correlations, if any, 
between the observed mutations and Vpr functions.  The transfection data acquired from this 
study reveals two sets of outliers when compared to the rest of the patients at basal level.  The 
first set includes the deduced amino acid sequences of PT 7 and PT 11.  PT7 who has been 
identified as a LTNP, has a variant sequence which exhibits an introduced truncation of the 
virus, while PT11, who has not been identified as either LTNP or RP, has a sequence variant 
which has incorporated the R80A mutation.  The other set includes deduced amino acid 
sequences of PT3 and PT14.  The sequence variant of PT3, also identified as a LTNP, also has a 
truncation introduced into its viral genome, while PT14 has a sequence variant that has 
introduced to mutation into its genome-Q3R and R77Q.  So even though these sets produced 
higher folds of transfection, the sequences are very similar in the fact that one from each set is 
either truncated or has had the introduction of at least one known Vpr mutation.  Further analysis 
of the two sets of outliers should provide a more significant correlation between the deduced 
amino acid sequences and the virus’ functional capabilities. 
HIV-1 Vpr is a unique non-structural protein that is associated with the virus particle. A 
number of functions necessary for viral replication and possibly for pathogenesis have been 
assigned to Vpr. A greater understanding of the complex interactions between HIV-1 gene 
product vpr and its possible role in HIV-mediated pathogenesis is clearly important.  For 
instance, this study has shown that due to the lack of apoptotic function it is possible that Vpr 
mediated bystander cell death could in fact be prevented.  Thusly in the case of LTNPs, the 
immune function has the chance of being restored by the CD4+ T-cells.  Such observations 
resulting from this study may lead to the development of new therapeutic interventions for 
AIDS. 
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8.0  FUTURE DIRECTIONS 
The basis for the research presented here is based upon the deduced amino acid 
sequences from patients within the MACS population.  From these sequences several point 
mutations as well as truncations have been observed and functional analyses have been carried 
out in order to better understand the different variants.  This study has been carried out for the 
main purpose of understanding the (linkage/interaction) between vpr gene 
mutations/polymorphisms and viral pathogenesis as well as the progression towards disease.  
Future studies involving the MACS patient clones will entail: 
(1) Deducing more Vpr amino acid sequences from the MACS patients. 
 By adding more Vpr clones to the already existing clones per patient will give a 
better understanding of the quasispecies represented within each patient.  This information will 
give more insight as to which mutation seem to dominate based on the environment of the host, 
i.e. LTNPs or Rps. 
(2) Further characterization of the Vpr clones for their known biological functions. 
 Additional analysis will be performed on the Vpr clones in order to identify 
changes from the normal biological functions to that of changes due to vpr mutations.  The 
functional analyses to be carried out include virus replication, cell cycle regulation, and immune 
dysregulation. 
(3) Sequential time point deduced amino acid sequences. 
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 It will be of interest to look at patient samples throughout their life, starting from 
right around the time of infection to well after their CD4+ T-cell counts have dropped.  By 
analyzing the deduced amino acid patient sequences at these time points, the emergence, and 
possible disappearance, of gene mutations, deletions, and, truncations can be observed and better 
understood. 
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